These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37531030)

  • 1. Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History.
    Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Takahashi H; Takayama T; Kawashima H; Yanagi Y
    Ophthalmol Ther; 2023 Oct; 12(5):2703-2712. PubMed ID: 37531030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
    Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.
    Takahashi H; Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Kawashima H; Yanagi Y
    Sci Rep; 2024 Apr; 14(1):9087. PubMed ID: 38643252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Comparison of Switching to Brolucizumab or Faricimab from Aflibercept in Neovascular AMD Patients.
    Kin A; Mizukami T; Ueno S; Mishima S; Shimomura Y
    Medicina (Kaunas); 2024 Jul; 60(7):. PubMed ID: 39064598
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
    Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
    Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration.
    Kishi M; Miki A; Kamimura A; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
    J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
    Yen WT; Wu CS; Yang CH; Chen YH; Lee CH; Hsu CR
    Sci Rep; 2024 Jan; 14(1):2485. PubMed ID: 38291069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Jpn J Ophthalmol; 2024 Mar; 68(2):83-90. PubMed ID: 38244172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
    Quah NQX; Javed KMAA; Arbi L; Hanumunthadu D
    Clin Ophthalmol; 2024; 18():1479-1490. PubMed ID: 38827773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-month outcomes of treatment with faricimab or aflibercept for neovascular age-related macular degeneration: a propensity score matching study in a Japanese population.
    Fukuda Y; Notomi S; Shiose S; Maehara Y; Kiyohara K; Fujiwara K; Hashimoto S; Kano K; Ishikawa K; Hisatomi T; Sonoda KH
    Graefes Arch Clin Exp Ophthalmol; 2024 Jul; ():. PubMed ID: 39073562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Nagashima T; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2023 Oct; 261(10):2945-2952. PubMed ID: 37195339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population.
    Ibrahim FNI; Teo KYC; Tan TE; Chan HH; Chandrasekaran PR; Lee SY; Tan ACS; Mathur R; Chan CM; Sim SS; Tan GSW; Yeo IYS; Cheung CMG
    Front Ophthalmol (Lausanne); 2023; 3():1346322. PubMed ID: 38982998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
    Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
    Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term outcomes of intravitreal faricimab for refractory neovascular age-related macular degeneration.
    Aljundi W; Munteanu C; Seitz B; Abdin AD
    Graefes Arch Clin Exp Ophthalmol; 2024 Sep; 262(9):2867-2874. PubMed ID: 38607409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
    Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C
    Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
    Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.
    Khanani AM; Aziz AA; Khan H; Gupta A; Mojumder O; Saulebayeva A; Abbey AM; Almeida DRP; Avery RL; Banda HK; Barakat MR; Bhandari R; Chang EY; Haug SJ; London NJS; Mein L; Sheth VS; Wolfe JD; Singer MA; Danzig CJ
    Eye (Lond); 2023 Dec; 37(17):3574-3581. PubMed ID: 37173428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
    Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
    Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration.
    Leung EH; Oh DJ; Alderson SE; Bracy J; McLeod M; Perez LI; Bottini A; Chin Yee D; Mukkamala K
    Clin Ophthalmol; 2023; 17():1287-1293. PubMed ID: 37181079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.